Table 1. Clinical characteristics of cases selected for analysis.
| Variable | Immunotherapy | Total | P value | ||
|---|---|---|---|---|---|
| Yes | No | ||||
| Total | 163 (100%) | 25,433 (100%) | 25,596 (100%) | ||
| Age | <0.0001 | ||||
| 70+ | 44 (27%) | 10,738 (42%) | 10,782 (42%) | ||
| <70 | 119 (73%) | 14,695 (58%) | 14,814 (58%) | ||
| Sex | 0.9867 | ||||
| Male | 86 (53%) | 13,402 (53%) | 13,488 (53%) | ||
| Female | 77 (47%) | 12,031 (47%) | 12,108 (47%) | ||
| Race | 0.0156 | ||||
| White | 145 (89%) | 20,754 (82%) | 20,899 (82%) | ||
| Other | 18 (11%) | 4,679 (18%) | 4,697 (18%) | ||
| Institution | 0.0002 | ||||
| Academic | 87 (53%) | 9,975 (39%) | 10,062 (39%) | ||
| Other | 76 (47%) | 15,458 (61%) | 15,534 (61%) | ||
| Insurance | 0.3018 | ||||
| Yes | 161 (99%) | 24,800 (98%) | 24,961 (98%) | ||
| No | 2 (1%) | 633 (2%) | 635 (2%) | ||
| Charlson-Deyo score | 0.3793 | ||||
| 0–1 | 152 (93%) | 23,222 (91%) | 23,374 (91%) | ||
| 2–3 | 11 (7%) | 2,211 (9%) | 2,222 (9%) | ||
| Histology | 0.0151 | ||||
| Adenocarcinoma | 113 (69%) | 19,666 (77%) | 19,779 (77%) | ||
| Other | 50 (31%) | 5,767 (23%) | 5,817 (23%) | ||
| Liver metastasis | 0.6513 | ||||
| Yes | 120 (74%) | 19,114 (75%) | 19,234 (75%) | ||
| No | 43 (26%) | 6,319 (25%) | 6,362 (25%) | ||
| Lung metastasis | 0.0006 | ||||
| Yes | 48 (29%) | 4,814 (19%) | 4,862 (19%) | ||
| No | 115 (71%) | 20,619 (81%) | 20,734 (81%) | ||
| Radiation | <0.0001 | ||||
| Yes | 19 (12%) | 1,261 (5%) | 1,280 (5%) | ||
| No | 144 (88%) | 24,172 (95%) | 24,316 (95%) | ||
| Chemotherapy | <0.0001 | ||||
| Yes | 133 (82%) | 16,342 (64%) | 16,475 (64%) | ||
| No | 30 (18%) | 9,091 (36%) | 9,121 (6%) | ||
| Primary location | 0.0005 | ||||
| Pancreatic Head | 42 (26%) | 9,223 (36%) | 9,265 (36%) | ||
| Other | 121 (74%) | 16,210 (64%) | 16,331 (64%) | ||
| Multi-agent chemotherapy | <0.0001 | ||||
| Yes | 115 (71%) | 12,881 (51%) | 12,996 (51%) | ||
| No | 48 (29%) | 12,552 (49%) | 12,600 (49%) | ||